4-O-Methylhonokiol.
More potent magnolia compound for anxiety and cognition A single neolignan from magnolia bark. In receptor work it modulates GABA-A signalling and binds the CB2 receptor, which is why it turns up in evening calm formulas.
Reviewed March 2026
- Category
- Compound
- Also filed under
- AnxietyCognitiveNeuroprotection
What 4-O-Methylhonokiol is, and what it does.
- Does it work
- Suits people who want this specific neolignan named on the label rather than a total neolignan figure. The human evidence sits with whole bark extracts, so this is early ground.
- How much to take
- Start with 50 to 100mg a day, in the evening and with a meal containing fat, since it hardly dissolves in water.
- Time to feel it
- Nobody has measured an onset in people for this compound on its own. What's published is receptor binding and animal work, so a human timeline would be guesswork.
- The first dose
- Day one is quiet in the published record. Nobody has measured a same-day response in people for this compound on its own.
- With regular use
- Weeks of daily use haven't been studied in people for this isolated compound. The human data on magnolia sits with whole bark extracts rather than this single neolignan.
- How well tolerated
- Tolerability hasn't been studied in people for the isolated compound. Magnolia extracts are well tolerated and can add to drowsiness, so check with your doctor if you take sedating medicine.
- How it feels
- Nobody has recorded the subjective experience of this compound alone. People taking magnolia extracts generally describe mild settling rather than sedation.
- The overlooked benefit
- It's a minor constituent of the bark, so a standardised extract may carry only traces of it. A label that means this compound has to name it, not total neolignans.
100 to 400mg a day is where 4-O-Methylhonokiol works.
Source: Kalman et al. 2008 Nutr J (n=89 RCT); Kuribara et al. 2000 J Pharm Pharmacol.
The proof, claim by claim.
These words describe the research, not the molecule's worth. Research strength is how much work stands behind one claim, and it is never a product score.
4-O-Methylhonokiol has emerging evidence. Based on 179+ studies.
- positive allosteric modulation at GABA-A receptorsIn vitro study
- cannabinoid CB2 receptor bindingIn vitro study
- calm behaviour in rodent modelsAnimal study
- a healthy inflammatory responseAnimal study
Questions people ask about 4-O-Methylhonokiol.
- When should I take it?
- Timing matters less than consistency. Pick a time that works for you and take it daily.
- Can I take it with other supplements?
- Usually fine. The main thing to watch is not doubling up on the same ingredient from different products. If you're on prescription meds, check with your pharmacist first.
- Any side effects to watch for?
- Most people tolerate it well at recommended doses. GI upset is the most common complaint with any supplement. Start with a lower dose and work up. If something feels off, stop and reassess.
- Who benefits most from this?
- People who've already covered the basics (diet, sleep, exercise) and want to fine-tune. It's not essential, but could be worthwhile for the right person.
Why these belong in the same formula. Each row says what the basis is, from settled biochemistry through to a trial that measured the pair.
4-O-methylhonokiol is a minor neolignan found in Magnolia officinalis and related species alongside the far more abundant magnolol and honokiol. A product supplying both delivers overlapping chemistry rather than two independent ingredients. Count total neolignan intake instead of adding them as separate items.
Magnolia neolignans act as positive allosteric modulators at GABA-A receptors in animal and receptor-binding studies, while theanine influences glutamate and GABA signalling by a different route. Both are used to support a calm state. Combining two agents that touch inhibitory signalling means counting the total effect on alertness.
A positive allosteric modulator increases the response to the receptor's own agonist rather than opening the channel itself, so it depends on GABA being present. Oral GABA crosses the blood brain barrier poorly, which limits how much of that interaction is realised. The receptor pharmacology is established; the practical outcome of the pair is not.
Melatonin works through MT1 and MT2 receptors on circadian timing, while magnolia neolignans work at GABA-A. The two levers are separate, which is why they appear together in night formulas. Additive drowsiness is the thing to count, and neither should be taken before driving.
Valerenic acid from valerian is described as a GABA-A modulator at the beta subunit, a different site from where magnolia neolignans are proposed to act. Combining two modulators of the same receptor complex compounds the effect. Regard the additive sedation as the meaningful point here.
Passionflower extracts show GABAergic activity in rodent behavioural models. Paired with a magnolia neolignan, the sedative load adds. This is a caution as much as a synergy, and it belongs on the label rather than in fine print.
Chamomile supplies apigenin, which binds the benzodiazepine site of the GABA-A receptor in binding assays. Magnolia neolignans modulate the same receptor complex from a different site. The overlap is receptor-level and preclinical, and the practical consequence is additive drowsiness.
Apigenin is a well-characterised ligand at the benzodiazepine site of GABA-A in binding studies. A neolignan modulating the same receptor complex from another site produces convergent signalling. The receptor chemistry is established; the human combination has not been studied.
Glycine is the main inhibitory neurotransmitter in the brainstem and spinal cord, acting at its own strychnine-sensitive receptor and as a co-agonist at NMDA receptors. That is separate chemistry from GABA-A modulation. Two inhibitory levers pulled together warrant counting total effect on alertness.
Magnesium sits in the NMDA receptor channel as a voltage-dependent block, damping excitatory signalling, and the glycinate carrier contributes glycine. Both sit on the inhibitory side of the same balance a GABA-A modulator works on. Established ion-channel pharmacology, not a study of the pair.
Neolignans such as magnolol, honokiol and their methylated derivatives are highly lipophilic and dissolve poorly in water. A medium-chain triglyceride carrier keeps them in solution in a softgel. The relationship is physical delivery chemistry.
Phospholipid emulsifiers disperse a lipophilic compound through the aqueous gut phase so it can reach the micellar route. Lecithin is used this way across neolignan and polyphenol products. This is formulation practice with settled physical chemistry behind it.
Magnolia neolignans are cleared largely by UGT-mediated glucuronidation, and piperine inhibits several UGT isoforms in the gut wall and liver. The result is higher systemic exposure to compounds handled that way. That is a real exposure shift and it applies to anything else in the formula cleared by the same route.
Caffeine blocks adenosine receptors to raise arousal, while a GABA-A positive modulator pushes in the opposite direction. Taking them together does not cancel cleanly, since they act on separate systems with different time courses. The pairing is worth flagging as opposing rather than complementary.
Ashwagandha withanolides are studied against cortisol and the stress axis, a different lever from receptor-level GABA-A modulation. Products combine the two for that reason. The grounding is each ingredient's own literature plus formulation practice, not a study of the combination.
Nothing specific on file for 4-O-Methylhonokiol. Match the label to the daily amount above, and tell your doctor what you take.
Not medical advice. Show the label to your pharmacist.What 4-O-Methylhonokiol actually does.
4-O-methylhonokiol is a biphenolic neolignan, the 4-O-methyl ether of honokiol, occurring naturally in the bark of Magnolia officinalis and related Magnolia species.
It sits in the same structural family as magnolol and honokiol, the two neolignans that make up the bulk of magnolia bark's characteristic chemistry.
Methylation of one phenolic hydroxyl raises lipophilicity relative to honokiol, which changes how the molecule partitions into membranes and how it is conjugated for excretion.
Free phenolic groups on neolignans are the primary sites for phase II glucuronidation and sulfation, which is the main clearance route for this compound class.
Where 4-O-Methylhonokiol comes from.
This is one specific compound out of magnolia tree bark, and it is only a small part of what is in that bark. Makers either pull it out of a bark extract using chromatography, which takes a lot of bark for a little compound, or they build it in a lab by adding a methyl group to honokiol, a related bark compound. Either way it barely dissolves in water, so it usually arrives already mixed into an oil or phospholipid base.
The same molecule is reached more than one way. Which route a given product used is a manufacturing choice, and the finished compound is the same either way.
The botanical route starts with stem, root or branch bark of Magnolia officinalis and related species, cultivated mainly in China. The synthetic route starts from honokiol, itself usually bark-derived, or from substituted allylphenol building blocks.
Dried, milled bark is extracted with ethanol or another organic solvent, which pulls the neolignan fraction dominated by magnolol and honokiol with 4-O-methylhonokiol as a minor component.
Where the compound is made rather than isolated, one phenolic hydroxyl of honokiol is methylated selectively. Total synthesis approaches build the biphenyl core by coupling substituted allylphenol units instead.
The target neolignan is separated from magnolol, honokiol and other bark constituents by column or preparative chromatography, then recrystallised. Natural abundance is low, so yield per kilogram of bark is small.
Identity and purity are confirmed by HPLC with a reference standard, supported by mass spectrometry and NMR for the isolated compound. Extract-grade material is instead declared on total honokiol and magnolol.
Supplied as a dry crystalline powder, or pre-dispersed in a triglyceride or phospholipid carrier because aqueous solubility is low.
Getting 4-O-Methylhonokiol from food.
The whole-food sources on file. A supplement closes the gap, it does not replace dinner.
A gram-for-gram figure (how much of each you would eat to match a dose) will appear here once it is sourced and reviewed. This page will not print a number it cannot cite.
The forms it comes in.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.